Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Skin Cancer01:30

Skin Cancer

6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Metastasis02:30

Metastasis

6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.2K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2026
Same author

Non-Temperature-Induced Antitumor Effects of Amplitude-Modulated Radiofrequency: Molecular and Functional Synergies with Radiotherapy.

Cancers·2026
Same author

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.

European urology·2026
Same author

Genomic evolution of high-risk soft tissue sarcomas under thermo- and chemotherapeutic selection pressure.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2025
Same author

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer.

Scientific reports·2025
Same author

Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

Related Experiment Video

Updated: Mar 6, 2026

Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

10.4K

Planning study for Merkel cell carcinoma based on the relapse pattern.

Ulrike Hoeller1, Tina Schubert1, Thomas Mueller1

  • 1Radiation Oncology, Charité University Medicine Berlin, Germany.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|March 13, 2017
PubMed
Summary
This summary is machine-generated.

This study developed a technique for radiation therapy of in-transit pathways in Merkel cell carcinoma. The planning study confirmed the feasibility of highly conformal irradiation for these pathways.

Keywords:
In transit metastasesMerkel cell carcinomaPlanning studySentinel node scintigraphy

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

788
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

10.4K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

788
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Merkel cell carcinoma (MCC) is an aggressive skin cancer with a high risk of recurrence.
  • In-transit metastases (IT) represent a significant challenge in MCC management.
  • Effective radiation techniques for IT are crucial for improving patient outcomes.

Purpose of the Study:

  • To develop and evaluate a technique for radiation therapy (RT) targeting in-transit pathways (IT) in Merkel cell carcinoma (MCC).
  • To establish feasibility of conformal RT for IT in MCC patients.

Main Methods:

  • A planning study involving five patients with MCC was conducted.
  • In-transit pathways were delineated using skin ink markings and planning CT scans.
  • Clinical target volume (CTV) and planning target volume (PTV) were defined, incorporating safety margins.
  • Volumetric Modulated Arc Therapy (VMAT) plans were analyzed for coverage and conformity.

Main Results:

  • The planning study demonstrated satisfactory PTV coverage, with Dmean at 100%±0% and D98% at 92.4%±2.24%.
  • High conformity was achieved, indicated by a homogeneity index (HI) of 0.095±0.01, conformation number (CN) of 0.84±0.01, and conformality index (CI) of 0.95±0.01.
  • The technique proved feasible for highly conformal irradiation of IT pathways.

Conclusions:

  • The planning study confirms the feasibility of highly conformal irradiation of in-transit pathways in Merkel cell carcinoma using individualized target delineation.
  • A prospective clinical study is underway to further evaluate the feasibility of RT for IT pathways in non-metastatic MCC patients.